Skip to main content
رجوع
IMVT logo

Immunovant, Inc.

جودة البيانات: 100%
IMVT
NASDAQ Healthcare Biotechnology
KWD 23.84
▼ KWD 0.54 (-2.21%)
القيمة السوقية: 4.85B
نطاق اليوم
KWD 23.28 KWD 24.40
نطاق 52 أسبوعًا
KWD 12.72 KWD 29.25
حجم التداول
1,345,567
متوسط 50 يوم / 200 يوم
KWD 26.10 / KWD 20.79
الإغلاق السابق
KWD 24.38

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E -11.7 0.4
P/B 6.9 2.9
ROE % -62.5 3.7
Net Margin % 3.9
Rev Growth 5Y % 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 35.670 +49.6%
Low: KWD 16.000 High: KWD 50.000
ربحية السهم المستقبلية
-KWD 2.634
الإيرادات المقدّرة
10 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 2.088
KWD 2.088 – KWD 2.088
1.3 B 11
FY2029 -KWD 1.374
-KWD 1.374 – -KWD 1.374
460 M 8
FY2028 -KWD 2.462
-KWD 3.810 – -KWD 1.471
110 M 13

النقاط الرئيسية

Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -376.63M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-62.46%
ROIC-46.44%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
0.00
Current Ratio11.16
Interest Coverage0.00

التقييم

P/E Ratio
-11.72
P/B Ratio6.86
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -413.84M
ROE -62.46% ROA -53.31%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -376.63M
ROIC -46.44% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 11.16
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -11.72 P/B Ratio 6.86
P/S Ratio N/A PEG Ratio -0.14
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 4.85B Enterprise Value 4.14B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 0.0 0.0 0.0 0.0
Net Income -413.84M -259.34M -210.96M -156.73M -107.43M
EPS (Diluted) -2.73 -1.88 -1.71 -1.43 -1.22
Gross Profit 0.0 0.0 0.0 0.0 0.0
Operating Income -438.15M -270.21M -208.28M -156.03M -108.12M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 776.22M 666.71M 405.84M 515.56M 412.49M
Total Liabilities 68.78M 48.96M 43.34M 45.74M 21.01M
Shareholders' Equity 707.45M 617.76M 362.49M 469.83M 391.48M
Total Debt 98,000.0 138,000.0 1.22M 2.36M 3.42M
Cash & Equivalents 713.97M 635.37M 376.53M 493.82M 400.15M
Current Assets 767.66M 665.77M 404.33M 512.93M 409.01M
Current Liabilities 68.78M 48.61M 43.30M 44.52M 18.77M